- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03420235
Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
IPF is a chronic disease with progressive scarring of the lung tissue (fibrosis), resulting in a poor prognosis and a devastating impact on the lives of patients and their families. Progressive shortness of breath, cough and fatigue are major factors influencing health-related quality of life (HRQOL) in patients with IPF. Recently two anti-fibrotic drugs became available that slow down disease progression. The availability of effective drugs for this devastating disease has importantly changed daily care and research in IPF. Currently, one of the major challenges in daily IPF care is the evaluation of how individual patients objectively and subjectively experience treatment and benefit from treatment. The use of information communication technology in health care, also named e-health, is a promising solution to improve the quality of care. E-health allows remote exchange of data between patients and health care professionals which enables monitoring, research and management of long term conditions. Also communication between patients and physicians, and physicians mutually, becomes more accessible. This creates an opportunity for earlier intervention by health care professionals, which may prevent a hospital admission. This might improve quality of life and reduce costs. Patients easily get access to up-to-date and tailored information, in an interactive way. By providing these tools, patients may better understand their health conditions and become actively involved in management of their own health care, which may lead to a better health status. An 'internet tool' for patients with IPF have been developed, providing information and enabling them to keep track of their own symptoms, HRQOL scores, medication use and lung function results.
In this study it will be investigated whether a home monitoring program improves disease-specific HRQOL for IPF patients through appropriate medication use and subsequently results in better objective and subjective outcomes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zuid-Holland
-
Rotterdam, Zuid-Holland, Netherlands, 3015 CE
- Erasmus MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients with a diagnosis of IPF according to the ATS 2011 criteria and about to start on anti-fibrotic treatment (either nintedanib or pirfenidone)
Exclusion Criteria:
- Not able to speak, read or write in Dutch
- No access to internet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control group
Control group will receive standard care alone.
|
|
EXPERIMENTAL: Home monitoring group
Intervention will consist of a home monitoring program added to standard care.
|
The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in the change in total score of King's brief Interstitial Lung Disease Health Status (K-BILD) questionnaire between the home monitoring group and the standard care group
Time Frame: 24 weeks after inclusion
|
Change in HRQOL assessed by the K-BILD, between control group and home monitoring group at the end of the study.
The K-BILD is a 15-item self-administered questionnaire on a 7-point response scale.
It has three domains: breathlessness and activities, psychological and chest symptoms.The domain and total score ranges are 0-100, with the higher scores corresponding with better HRQL.
|
24 weeks after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in the change in total score of King's brief Interstitial Lung Disease Health Status (K-BILD) questionnaire between the home monitoring group and the standard care group
Time Frame: 12 weeks after inclusion
|
Change in HRQOL assessed by the K-BILD, between control group and home monitoring group.
The K-BILD is a 15-item self-administered questionnaire on a 7-point response scale.
It has three domains: breathlessness and activities, psychological and chest symptoms.The domain and total score ranges are 0-100, with the higher scores corresponding with better HRQL.
|
12 weeks after inclusion
|
Patient-reported outcome (PRO) scores (GRC)
Time Frame: 12 weeks after inclusion
|
Patients will fill in the Global Rating of Change (GRC) which measures whether QoL has improved or deteriorated over a certain period of time, with scores range from -7 to +7, with positive scores corresponding with improvement in QoL
|
12 weeks after inclusion
|
Patient-reported outcome (PRO) scores (EQ5D)
Time Frame: 12 weeks after inclusion
|
Patients will complete the EQ-5D-5L questionnaire, a standardized instrument to measure health outcomes in two components: health description and valuation.
It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a 5-point scale.
From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better QoL.
In the valuation part the patients' general health status is evaluated using a VAS-score from 0 to 100, with a higher score representing a better QoL.
|
12 weeks after inclusion
|
Patient-reported outcome (PRO) scores (HADS)
Time Frame: 12 weeks after inclusion
|
Patients will complete the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire with 7 questions in the domain anxiety and 7 questions in the domain depression on a 0-3 Likert scale.
Higher values represent higher anxiety and depression levels, with a maximum of 21 point in both domains.
There is a cut-off score of 8/21 for anxiety and depression.
|
12 weeks after inclusion
|
Patient-reported outcome (PRO) scores (HADS)
Time Frame: 24 weeks after inclusion
|
Patients will complete the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire with 7 questions in the domain anxiety and 7 questions in the domain depression on a 0-3 Likert scale.
Higher values represent higher anxiety and depression levels, with a maximum of 21 point in both domains.
There is a cut-off score of 8/21 for anxiety and depression.
|
24 weeks after inclusion
|
Patient-reported outcome (PRO) scores (EQ5D)
Time Frame: 24 weeks after inclusion
|
Patients will complete the EQ-5D-5L questionnaire, a standardized instrument to measure health outcomes in two components: health description and valuation.
It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a 5-point scale.
From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better QoL.
In the valuation part the patients' general health status is evaluated using a VAS-score from 0 to 100, with a higher score representing a better QoL.
|
24 weeks after inclusion
|
Patient-reported outcome (PRO) scores (GRC)
Time Frame: 24 weeks after inclusion
|
Patients will complete the Global Rating of Change (GRC) which measures whether QoL has improved or deteriorated over a certain period of time, with scores range from -7 to +7, with positive scores corresponding with improvement in QoL.
|
24 weeks after inclusion
|
Patient expectations and satisfaction with medication (PESaM scores)
Time Frame: Baseline and 12 weeks after inclusion
|
Correlation between patient expectations with medication and consecutive experiences measured with the PESaM questionnaire which assess patient expectations at baseline in an 11-item questionnaire and patient experiences and side-effects with medication after 12 weeks in a 26-item questionnaire on a 0-4 Likert scale.
For each question it is different whether a higher score represents better or worse outcomes.
|
Baseline and 12 weeks after inclusion
|
Patient expectations and satisfaction with medication (PESaM scores)
Time Frame: Baseline and 24 weeks after inclusion
|
Correlation between patient expectations with medication and consecutive experiences measured with the PESaM questionnaire which assess patient expectations at baseline in an 11-item questionnaire and patient experiences and side-effects with medication after 24 weeks in a 26-item questionnaire on a 0-4 Likert scale.
For each question it is different whether a higher score represents better or worse outcomes.
|
Baseline and 24 weeks after inclusion
|
Patient satisfaction with medication (PESaM scores)
Time Frame: 24 weeks after inclusion
|
Overall patient satisfaction with medication after 24 weeks resulting from the 26-item PESaM questionnaire.
For each question it is different whether a higher score represents better or worse outcomes
|
24 weeks after inclusion
|
Patient satisfaction with the care process
Time Frame: 24 weeks after inclusion
|
Evaluation and satisfaction questionnaire at the end of the study.
10-item questionnaire with answers on a scale from -5 to 5, with higher scores corresponding with higher satisfaction
|
24 weeks after inclusion
|
Number of patients who discontinue use of medication, pills used and pills wasted
Time Frame: 24 weeks after inclusion
|
Every week patients register whether they missed pills (and the amount of pills wasted).
Discontinuation or switch of medication is registered both by patients and researchers.
|
24 weeks after inclusion
|
Amount of contacts with healthcare providers and number of visits per patient
Time Frame: 24 weeks after inclusion
|
During the study patients register their contacts with healthcare providers (hospital visits, general practitioner visits, physiotherapist, dietician, psychologist), after 24 weeks the amount of contacts will be assessed
|
24 weeks after inclusion
|
FVC decline
Time Frame: 12 weeks after inclusion
|
FVC decline measured by hospital-based spirometry and daily home spirometry
|
12 weeks after inclusion
|
FVC decline
Time Frame: 24 weeks after inclusion
|
FVC decline measured by hospital-based spirometry and daily home spirometry
|
24 weeks after inclusion
|
Personal goal of patient defined at start of study
Time Frame: 24 weeks after inclusion
|
Change in score of personal goal.
Patients define a personal goal at the start of the study and they score on a scale from 0 -10 how far they have reached their goal
|
24 weeks after inclusion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Home monitoring values of FVC compared to in hospital values of lung function
Time Frame: 12 weeks after inclusion
|
Home monitoring values compared to in hospital values of lung function
|
12 weeks after inclusion
|
Home monitoring values of FVC compared to in hospital values of lung function
Time Frame: 24 weeks after inclusion
|
Home monitoring values compared to in hospital values of lung function
|
24 weeks after inclusion
|
Correlation between FVC measurements and K-BILD
Time Frame: 12 weeks after inclusion
|
Correlation between FVC and K-BILD.
The K-BILD is a 15-item self-administered questionnaire on a 7-point response scale.
It has three domains: breathlessness and activities, psychological and chest symptoms.The domain and total score ranges are 0-100, with the higher scores corresponding with better HRQL.
|
12 weeks after inclusion
|
Correlation between FVC measurements and K-BILD
Time Frame: 24 weeks after inclusion
|
Correlation between FVC and K-BILD.
The K-BILD is a 15-item self-administered questionnaire on a 7-point response scale.
It has three domains: breathlessness and activities, psychological and chest symptoms.The domain and total score ranges are 0-100, with the higher scores corresponding with better HRQL.
|
24 weeks after inclusion
|
Correlation between FVC measurements and EQ5D
Time Frame: 12 weeks after inclusion
|
Correlation between FVC and EQ5D.
The EQ5D is a standardized instrument to measure health outcomes in two components: health description and valuation.
It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a 5-point scale.
From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better QoL.
In the valuation part the patients' general health status is evaluated using a VAS-score from 0 to 100, with a higher score representing a better QoL.
|
12 weeks after inclusion
|
Correlation between FVC measurements and EQ5D
Time Frame: 24 weeks after inclusion
|
Correlation between FVC and EQ5D.
The EQ5D is a standardized instrument to measure health outcomes in two components: health description and valuation.
It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a 5-point scale.
From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better QoL.
In the valuation part the patients' general health status is evaluated using a VAS-score from 0 to 100, with a higher score representing a better QoL.
|
24 weeks after inclusion
|
Correlation between FVC measurements and HADS
Time Frame: 12 weeks after inclusion
|
Correlation between FVC and HADS.
The HADS is a 14-item questionnaire with 7 questions in the domain anxiety and 7 questions in the domain depression on a 0-3 Likert scale.
Higher values represent higher anxiety and depression levels, with a maximum of 21 point in both domains.
There is a cut-off score of 8/21 for anxiety and depression.
|
12 weeks after inclusion
|
Correlation between FVC measurements and HADS
Time Frame: 24 weeks after inclusion
|
Correlation between FVC and HADS.
The HADS is a 14-item questionnaire with 7 questions in the domain anxiety and 7 questions in the domain depression on a 0-3 Likert scale.
Higher values represent higher anxiety and depression levels, with a maximum of 21 point in both domains.
There is a cut-off score of 8/21 for anxiety and depression.
|
24 weeks after inclusion
|
Correlation between FVC measurements and GRC
Time Frame: 12 weeks after inclusion
|
Correlation between FVC and GRC.
The Global Rating of Change (GRC) measures whether QoL has improved or deteriorated over a certain period of time, with scores range from -7 to +7, with positive scores corresponding with improvement in QoL.
|
12 weeks after inclusion
|
Correlation between FVC measurements and GRC
Time Frame: 24 weeks after inclusion
|
Correlation between FVC and GRC.
The Global Rating of Change (GRC) measures whether QoL has improved or deteriorated over a certain period of time, with scores range from -7 to +7, with positive scores corresponding with improvement in QoL.
|
24 weeks after inclusion
|
Correlation between VAS score on stability of IPF scored by patients and healthcare providers
Time Frame: Baseline
|
Both patients and healthcare providers will score a Visual Analogue Scale (VAS) with a score between 0 (not stable) and 10 (very stable) on stability of IPF at baseline.
Correlation between the VAS scores from patients and healthcare providers will be assessed.
|
Baseline
|
Correlation between VAS score on stability of IPF scored by patients and healthcare providers
Time Frame: 12 weeks
|
Both patients and healthcare providers will score the stability of their IPF on a Visual Analogue Scale (VAS).
The visual analogue scale has a score between 0 (very unstable) and 10 (very stable), therefore higher scores correspond with better outcomes.
Correlation between the VAS scores from patients and healthcare providers will be assessed at 12 weeks.
|
12 weeks
|
Correlation between VAS score on stability of IPF scored by patients and healthcare providers
Time Frame: 24 weeks
|
Both patients and healthcare providers will score the stability of their IPF on a Visual Analogue Scale (VAS).
The visual analogue scale has a score between 0 (very unstable) and 10 (very stable), therefore higher scores correspond with better outcomes.
Correlation between the VAS scores from patients and healthcare providers will be assessed at 24 weeks.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marlies Wijsenbeek, MD PhD, Erasmus Medical Center
Publications and helpful links
General Publications
- Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res. 2020 Jul 23;21(1):196. doi: 10.1186/s12931-020-01458-1.
- Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, Wijsenbeek MS. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2020 Aug 1;202(3):393-401. doi: 10.1164/rccm.202002-0328OC.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL62925.078.17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Bristol-Myers SquibbCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
-
Xfibra, Inc.Not yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on Home monitoring program
-
Federico II UniversityCompleted
-
Silesian Centre for Heart DiseasesNational Center for Research and Development, PolandCompleted
-
Deutsches Herzzentrum MuenchenCompletedImprovement of Treatment SatisfactionGermany
-
Pennington Biomedical Research CenterLouisiana State University Health Care Services DivisionCompletedHypertension | Obesity | Diabetes | OverweightUnited States
-
Biotronik SE & Co. KGTerminatedHeart Block | Bradycardia | Sick Sinus SyndromeUnited Kingdom
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular Tachycardia | Congestive Heart FailureDenmark, Germany, Israel, Australia, Austria, Czech Republic, Latvia
-
Biotronik FranceBiotronik SE & Co. KGCompletedBradycardia | Pacemaker, ArtificialFrance
-
Biotronik SE & Co. KGTerminatedAtrial Fibrillation | Heart Failure (HF)France, Czech Republic, Germany, Netherlands, Belgium, Sweden, United Kingdom
-
Western University, CanadaCompleted
-
Sheba Medical CenterEarlySense Ltd.UnknownMyocardial Infarction | Cardiac SurgeryIsrael